vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Dine Brands Global, Inc. (DIN). Click either name above to swap in a different company.
Dine Brands Global, Inc. is the larger business by last-quarter revenue ($217.6M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -5.6%, a 41.1% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 6.3%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-8.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 2.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
ADMA vs DIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $217.6M |
| Net Profit | $49.4M | $-12.2M |
| Gross Margin | 63.8% | 42.4% |
| Operating Margin | 45.1% | -7.6% |
| Net Margin | 35.5% | -5.6% |
| Revenue YoY | 18.4% | 6.3% |
| Net Profit YoY | -55.9% | -336.1% |
| EPS (diluted) | $0.20 | $-0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $217.6M | ||
| Q3 25 | $134.2M | $216.2M | ||
| Q2 25 | $122.0M | $230.8M | ||
| Q1 25 | $114.8M | $214.8M | ||
| Q4 24 | $117.5M | $204.8M | ||
| Q3 24 | $119.8M | $195.0M | ||
| Q2 24 | $107.2M | $206.3M | ||
| Q1 24 | $81.9M | $206.2M |
| Q4 25 | $49.4M | $-12.2M | ||
| Q3 25 | $36.4M | $7.3M | ||
| Q2 25 | $34.2M | $13.8M | ||
| Q1 25 | $26.9M | $8.2M | ||
| Q4 24 | $111.9M | $5.2M | ||
| Q3 24 | $35.9M | $19.1M | ||
| Q2 24 | $32.1M | $23.2M | ||
| Q1 24 | $17.8M | $17.5M |
| Q4 25 | 63.8% | 42.4% | ||
| Q3 25 | 56.3% | 39.1% | ||
| Q2 25 | 55.1% | 40.0% | ||
| Q1 25 | 53.2% | 42.0% | ||
| Q4 24 | 53.9% | 41.7% | ||
| Q3 24 | 49.8% | 47.8% | ||
| Q2 24 | 53.6% | 48.1% | ||
| Q1 24 | 47.8% | 47.2% |
| Q4 25 | 45.1% | -7.6% | ||
| Q3 25 | 38.0% | 4.7% | ||
| Q2 25 | 35.1% | 8.2% | ||
| Q1 25 | 30.4% | 6.0% | ||
| Q4 24 | 32.6% | 3.8% | ||
| Q3 24 | 33.1% | 13.6% | ||
| Q2 24 | 36.6% | 15.1% | ||
| Q1 24 | 26.7% | 11.7% |
| Q4 25 | 35.5% | -5.6% | ||
| Q3 25 | 27.1% | 3.4% | ||
| Q2 25 | 28.1% | 6.0% | ||
| Q1 25 | 23.4% | 3.8% | ||
| Q4 24 | 95.2% | 2.5% | ||
| Q3 24 | 30.0% | 9.8% | ||
| Q2 24 | 29.9% | 11.2% | ||
| Q1 24 | 21.7% | 8.5% |
| Q4 25 | $0.20 | $-0.79 | ||
| Q3 25 | $0.15 | $0.48 | ||
| Q2 25 | $0.14 | $0.89 | ||
| Q1 25 | $0.11 | $0.53 | ||
| Q4 24 | $0.45 | $0.35 | ||
| Q3 24 | $0.15 | $1.24 | ||
| Q2 24 | $0.13 | $1.50 | ||
| Q1 24 | $0.08 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $128.2M |
| Total DebtLower is stronger | $72.1M | $1.2B |
| Stockholders' EquityBook value | $477.3M | $-273.9M |
| Total Assets | $624.2M | $1.7B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $128.2M | ||
| Q3 25 | $61.4M | $167.9M | ||
| Q2 25 | $90.3M | $194.2M | ||
| Q1 25 | $71.6M | $186.5M | ||
| Q4 24 | $103.1M | $186.7M | ||
| Q3 24 | $86.7M | $169.6M | ||
| Q2 24 | $88.2M | $153.5M | ||
| Q1 24 | $45.3M | $145.0M |
| Q4 25 | $72.1M | $1.2B | ||
| Q3 25 | $72.4M | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $72.3M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $477.3M | $-273.9M | ||
| Q3 25 | $431.2M | $-231.9M | ||
| Q2 25 | $398.3M | $-212.5M | ||
| Q1 25 | $373.4M | $-215.7M | ||
| Q4 24 | $349.0M | $-216.0M | ||
| Q3 24 | $231.9M | $-216.7M | ||
| Q2 24 | $188.3M | $-231.7M | ||
| Q1 24 | $153.7M | $-244.8M |
| Q4 25 | $624.2M | $1.7B | ||
| Q3 25 | $568.7M | $1.8B | ||
| Q2 25 | $558.4M | $1.8B | ||
| Q1 25 | $510.6M | $1.8B | ||
| Q4 24 | $488.7M | $1.8B | ||
| Q3 24 | $390.6M | $1.7B | ||
| Q2 24 | $376.4M | $1.7B | ||
| Q1 24 | $350.9M | $1.7B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $5.7M |
| Free Cash FlowOCF − Capex | $34.6M | $-8.6M |
| FCF MarginFCF / Revenue | 24.8% | -3.9% |
| Capex IntensityCapex / Revenue | 0.8% | 6.6% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $53.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $5.7M | ||
| Q3 25 | $13.3M | $30.2M | ||
| Q2 25 | $21.1M | $37.0M | ||
| Q1 25 | $-19.7M | $16.1M | ||
| Q4 24 | $50.2M | $30.5M | ||
| Q3 24 | $25.0M | $25.5M | ||
| Q2 24 | $45.6M | $21.6M | ||
| Q1 24 | $-2.2M | $30.6M |
| Q4 25 | $34.6M | $-8.6M | ||
| Q3 25 | $-1.1M | $18.1M | ||
| Q2 25 | $18.7M | $31.0M | ||
| Q1 25 | $-24.4M | $12.8M | ||
| Q4 24 | $47.5M | $26.7M | ||
| Q3 24 | $24.0M | $22.0M | ||
| Q2 24 | $43.6M | $18.2M | ||
| Q1 24 | $-4.6M | $27.2M |
| Q4 25 | 24.8% | -3.9% | ||
| Q3 25 | -0.8% | 8.4% | ||
| Q2 25 | 15.3% | 13.4% | ||
| Q1 25 | -21.2% | 6.0% | ||
| Q4 24 | 40.4% | 13.0% | ||
| Q3 24 | 20.0% | 11.3% | ||
| Q2 24 | 40.7% | 8.8% | ||
| Q1 24 | -5.6% | 13.2% |
| Q4 25 | 0.8% | 6.6% | ||
| Q3 25 | 10.7% | 5.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 4.1% | 1.5% | ||
| Q4 24 | 2.3% | 1.9% | ||
| Q3 24 | 0.9% | 1.8% | ||
| Q2 24 | 1.9% | 1.7% | ||
| Q1 24 | 2.9% | 1.6% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 4.12× | ||
| Q2 25 | 0.62× | 2.68× | ||
| Q1 25 | -0.73× | 1.97× | ||
| Q4 24 | 0.45× | 5.88× | ||
| Q3 24 | 0.70× | 1.34× | ||
| Q2 24 | 1.42× | 0.93× | ||
| Q1 24 | -0.12× | 1.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
